T Cell News and Research

Latest T Cell News and Research

EMA reviews CTI's Pixuvri Marketing Authorization Application for NHL

Cell Therapeutics, Inc. announced today that CTI's Marketing Authorization Application seeking approval for Pixuvri (pixantrone dimaleate) for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma was validated and accepted for review by the European Medicines Agency.

18 Nov 2010

Scientists solve structure of key protein from Lassa virus

Scientists at Emory University and the University of St. Andrews have solved the structure of a key protein from Lassa virus, which is endemic to West Africa and can cause a deadly hemorrhagic fever.

18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Accentia and Biovest exit Chapter 11 as fully restructured organizations

Accentia Biopharmaceuticals, Inc. announced that, effective today, the Company and its majority-owned subsidiary, Biovest International, Inc., have both successfully completed their reorganizations. Pursuant to their respective Plans of Reorganization approved by the bankruptcy court, Accentia and Biovest have now formally exited Chapter 11 as fully restructured organizations.

18 Nov 2010

UC Berkeley receives $16.5 million to support three research centers to examine children's health

Researchers at the University of California, Berkeley's School of Public Health are getting $16.5 million to support three research centers as part of a federal initiative to examine the environmental factors influencing children's health.

18 Nov 2010

Scientists develop new method for detecting functional sites on proteins

A team led by scientists from The Scripps Research Institute has developed a powerful new method for detecting functional sites on proteins. The technique may have broad applications in basic research and drug development.

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Inovio achieves positive results in Phase I PENNVAX-B study for HIV

Inovio Pharmaceuticals, Inc. , a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved high vaccine-induced response rates and strong magnitude of immune responses in its Phase I clinical study of PENNVAX-B, a DNA vaccine for the prevention of HIV infection.

18 Nov 2010

Researchers discover NG2+ cells may impact ALS disease progression

By tracking the fate of a group of immature cells that persist in the adult brain and spinal cord, Johns Hopkins researchers discovered in mice that these cells undergo dramatic changes in ALS, also known as Lou Gehrig's disease.

18 Nov 2010

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.

18 Nov 2010

Researchers reveal mechanism of early-stage anthrax infection

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have determined a key mechanism by which Bacillus anthracis bacteria initiate anthrax infection despite being greatly outnumbered by immune system scavenger cells. The finding, made by studying genetically modified mice, adds new detail to the picture of early-stage anthrax infection and supports efforts to develop vaccines and drugs that would block this part of the cycle.

18 Nov 2010

Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented two posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics," in Berlin, Germany.

18 Nov 2010

miR765 RNA may play a role in development of heart failure: Research

Researchers at the University of Cincinnati (UC) have found a potential genetic target for heart disease, which could lead to therapies to prevent the development of the nation's No. 1 killer in its initial stages.

18 Nov 2010

European study on fat stem cells could help treat heart attack

Emerging Healthcare Solutions, Inc. anticipates the results of a new European study on treating heart attacks with stem cells taken from patients' belly fat.

18 Nov 2010

Statins activate bacterial-killing properties of white blood cells

Widely prescribed for their cholesterol-lowering properties, recent clinical research indicates that statins can produce a second, significant health benefit: lowering the risk of severe bacterial infections such as pneumonia and sepsis.

18 Nov 2010

New theoretical model could develop novel clinical decision making in cancer research

Schonfeld, a University of Illinois at Chicago professor of electrical and computer engineering, is studying gene expression and interactions in ways that are analogous to the workings of electrical or computer networks. He is project director and principal investigator of a four-year, $1.2 million National Institutes of Health grant.

18 Nov 2010

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today announced achievement of a US$4.0 million milestone payment from its development partner, Endo Pharmaceuticals Inc. This milestone is the fourth achieved by Bioniche subsequent to the parties executing their agreement in July, 2009.

18 Nov 2010

BioSante announces sale of oncolytic virus technology to Cold Genesys

BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.

18 Nov 2010

Researchers are revolutionizing treatment of cardiovascular disease through regenerative stem cell therapy

Northwestern Medicine physician researchers are revolutionizing treatment of cardiovascular disease by utilizing patients' own stem cells to regenerate heart and vascular tissue.

18 Nov 2010

VX-770 drug candidate improves lung function in people with cystic fibrosis

In a study published in this week's New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups.

18 Nov 2010

T Cell News and Research

Latest T Cell News and Research

EMA reviews CTI's Pixuvri Marketing Authorization Application for NHL

Scientists solve structure of key protein from Lassa virus

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Accentia and Biovest exit Chapter 11 as fully restructured organizations

UC Berkeley receives $16.5 million to support three research centers to examine children's health

Scientists develop new method for detecting functional sites on proteins

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Inovio achieves positive results in Phase I PENNVAX-B study for HIV

Researchers discover NG2+ cells may impact ALS disease progression

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Researchers reveal mechanism of early-stage anthrax infection

Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium

miR765 RNA may play a role in development of heart failure: Research

European study on fat stem cells could help treat heart attack

Statins activate bacterial-killing properties of white blood cells

New theoretical model could develop novel clinical decision making in cancer research

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

BioSante announces sale of oncolytic virus technology to Cold Genesys

Researchers are revolutionizing treatment of cardiovascular disease through regenerative stem cell therapy

VX-770 drug candidate improves lung function in people with cystic fibrosis

Immunology eBook

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Data management challenges in scientific research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Data management challenges in scientific research

Newsletters you may be interested in